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Highlights
REDUCING INCARCERATION WILL 
REDUCE HARM
One in five people in prison worldwide is held 
for drug offences, and 90% of people who inject 
drugs will be incarcerated at some point in their 
life. People in prison are at greater risk of HIV, 
hepatitis C, tuberculosis and COVID-19. When 
they are released from prison, their risk of 
overdose increases by up to 69-times. 
States must support people to live healthy 
lives by not putting them in prison and by 
promoting alternatives to incarceration.
PROVIDING HARM REDUCTION 
IN PRISONS IS A HUMAN RIGHTS 
OBLIGATION
People in prison retain their human rights, 
which includes their right to health. By 
withholding health services such as harm 
reduction from them, states are violating this 
right. In some cases, withholding essential 
services like opioid agonist therapy amounts 
to torture. The UN Special Rapporteur on 
Health, the European Convention on Human 
Rights, and the Nelson Mandela Rules on the 
treatment of prisoners all oblige states to 
provide health services in prisons.
States must provide harm reduction 
in prisons to meet their human rights 
obligations.
HARM REDUCTION IN PRISONS IS 
AN EFFECTIVE AND SAFE PUBLIC 
HEALTH MEASURE
Harm reduction works. Robust evidence 
shows that harm reduction services reduce 
transmission of HIV and viral hepatitis, reduce 
risk behaviours, reduce deaths from all causes, 
and can even reduce chances of people coming 
back to prison. This is why the World Health 
Organisation, UNAIDS and UN Office on Drugs 
and Crime all support harm reduction in 
prisons.
States must protect the health of people 
who use drugs by providing harm 
reduction services in prisons.
PEOPLE IN PRISON ARE SEVERELY 
UNDERSERVED BY HARM 
REDUCTION SERVICES
Even though states are obliged to provide 
the same standard of healthcare inside and 
outside prisons, when it comes to harm 
reduction, they do not do so. In nearly a third 
of countries where opioid agonist therapy is 
available, people in prison have no access. In 
88% of countries where needle and syringe 
programmes operate, there are none in 
prisons. Even where services are available in 
prisons, there are frequently barriers that make 
them inaccessible in practice.
States must ensure that harm reduction 
services are available and accessible in 
prisons.
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Reducing incarceration will reduce harm
Over 11 million people are imprisoned worldwide today, the 
highest number ever recorded.[1] Globally, the dominant 
response to drugs remains prohibition-based drug policies 
backed by criminal sanctions that have contributed to the 
increase in the prison population. 
Despite some moves towards the decriminalisation and 
regulation of drugs, drug offences remain one of the 
biggest drivers of incarceration. At least one in five people 
in prison globally is held for drug-related offences.[1,2] 
Approximately half a million people are serving sentences 
for personal drug possession.[3] UNAIDS estimates that up 
to 90% of people who inject drugs will be incarcerated at 
some point in their life.[4] There are also more than 400,000 
people detained in forced rehabilitation and compulsory 
drug detention centres in Asia alone, with forms of 
compulsory drug treatment also existing in Latin America 
and the Caribbean, Eastern Europe and Central Asia and 
elsewhere.[5] This punitive approach has the greatest 
impact on already marginalised populations, including 
women, racial and ethnic minorities, indigenous people 
and foreign nationals.[2] 
Incarceration is also an enormous waste of money and 
resources. Over USD 100 billion is spent globally on drug 
law enforcement every year, but just USD 131 million 
was spent on harm reduction in low- and middle-income 
countries in 2019. This means that we spend more than 
500 times the amount on punitive responses than we 
do on life-saving services for people who use drugs.[6–8]
Systematic reviews of evidence find that there is no clear 
link between imprisonment and crime rates or between 
compulsory treatment and drug use.[9,10] In fact, there is 
more evidence for links between reduced welfare systems 
and social inequality, and increased imprisonment 
rates.[3,9,11] Nevertheless, in many countries, and even more 
so in the context of a surge of oppressive regimes in many 
parts of the world, the punitive “lock them up” response to 
drugs remains the easiest answer to a complex issue. 
PEOPLE IN PRISON NEED HARM REDUCTION 
SERVICES
According to global statistics, people who use drugs 
make up about one-third to one-half of the world’s prison 
population.[12] The use of drugs in closed settings should 
come as no surprise. People in prison require access 
to harm reduction services. In fact, the increased risk of 
overdose, HIV, viral hepatitis and tuberculosis in closed 
settings means that harm reduction interventions have 
even greater potential in prisons.
In European countries, between 2% and 55% of people in 
prison reported injecting drugs while incarcerated.[13] Not 
only is injecting drug use documented in prisons in every 
region of the world, but studies demonstrate that people in 
prison are much more likely to share injecting equipment 
than those outside.[12,14] This, alongside overcrowding, poor 
hygiene standards and low quality and inaccessible health 
services make prisons places where infectious diseases 
spread easily.[15] Sharing injecting equipment has been 
linked to outbreaks of HIV in prisons in Iran, Lithuania, 
Thailand, the United Kingdom and Ukraine.[12] Globally, 
3.2% of prisoners are living with HIV and 15.1% are living 
with hepatitis C, figures which far outstrip prevalence in the 
broader community, and prevalence among people who 
inject drugs in prison is even higher.[16]
It is not just about infections. People in prison are also 
disproportionately vulnerable to overdose, both during 
their sentence and immediately after their release. Studies 
show that male and female prisoners are 19 and 69 times 
more likely, respectively, to die from an overdose than the 
non-prison population, with the first two weeks following 
release identified as particularly dangerous.[17–19] This may 
be related to a decrease in tolerance, drug purity variations, 
and changes in drug use behaviour.
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RACE, INCARCERATION AND DRUG POLICY
In a 2015 study on the impact of drug laws on 
human rights, the UN High Commissioner for Human 
Rights acknowledged that people of colour “may be 
particularly subject to discrimination in the context 
of drug enforcement efforts.”[20] The evidence for 
this is clear. Globally, the criminalisation of drugs 
perpetuates injustice, and people of colour are 
discriminated against at every stage of the judicial 
process.
In the United States, Black people are over three times 
more likely to experience arrest for drug offences by 
the age of 29 than white people.[21]  This pattern is 
repeated around the world: in South Africa, stop-and-
search campaigns disproportionately target Black 
communities, and in the Western Cape ‘coloured’ 
citizens are more than twice as likely to be arrested 
for drug possession than other racial groups.[22] In 
the United Kingdom, Black people are stopped and 
searched for drugs at nine times the rate of white 
people, despite the ‘find’ rate for drugs being lower 
among Black people than white people.[23]
Racial disparities in sentencing for drug offences 
mean that people of colour are not only incarcerated 
more often, but also for longer sentences. In Brazil, 
Black people are more likely to be sentenced for 
drug trafficking, rather than possession, with only 
5% of trafficking cases downgraded to possession 
compared with 50% for white people.[24] In the United 
Kingdom, the chance of receiving a prison sentence 
in a drug case is 240% higher for people of colour 
compared with white people.[25]
As a result of racial disparities in policing and 
sentencing, Black men are incarcerated at five times 
the rate of white men in the United States, and more 
than one third of all federal prisoners are Black, 
despite comprising only 13% of the population, 
meaning their representation is almost three times 
that in the general population. In Australia and New 
Zealand, incarceration rates for Indigenous groups 
are vastly higher than for the white population. 
In Australia, Aboriginal and Torres Strait Islander 
people make up 3% of the population, but 28% of 
the prison population; in New Zealand, Māori people 
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Harm reduction in prisons is a human rights obligation
Under international human rights law, persons deprived 
of their liberty retain all fundamental rights and freedoms, 
apart from those that are unavoidably restricted by the fact 
of their incarceration.[29] Therefore, people in prison have 
a right to health, like everyone else. The Nelson Mandela 
Rules (aka the UN Standard Minimum Rules for the 
Treatment of Prisoners) state that people in prison must 
have access to the same standard of care as they would 
outside prison, and that health services must ensure 
continuity of treatment including for drug dependence.[30]
In closed settings, the right to health and the right to freedom 
from torture and ill treatment are interdependent: denying 
people’s right to health can amount to torture.[31] Several 
international and regional human rights mechanisms 
clarify states’ obligations to provide essential health 
services to people who use drugs in prisons. For example, 
the UN Special Rapporteur on the Right to Health has 
recognised the provision of harm reduction in prisons as 
a legally binding obligation under the right to health on 
several occasions.[32] In 2016, the European Court of 
Human Rights ruled that denying OAT to people in prison 
is a violation of the European Convention on Human 
Rights’ prohibition of cruel, inhuman and degrading 
punishment.[33]
More broadly, the UN Working Group on Arbitrary 
Detention has recognised that over incarceration for 
drug-related offences contributes significantly to prison 
overcrowding. In its 2015 report, the same Working Group 
stated that compulsory detention for drug “rehabilitation” 
is contrary to scientific evidence and inherently arbitrary. 
Involuntary confinement of those who use or are 
suspected of using drugs must be avoided.[34] The 
UN Common Position on Incarceration also calls for 
a reduction in the use of incarceration, as well as the 
expansion of health programmes for people who use 
drugs in prison.[35]
Overall, the UN Common Position on Drugs calls for 
the decriminalisation of drug possession for personal 
use. This is endorsed by the Chief Executives Board for Co-
ordination which represents all 31 UN agencies including 
the UN Office on Drugs and Crime, the World Health 
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COVID-19: A MISSED OPPORTUNITY TO ADDRESS OVERCROWDING  
AND PRISON REFORM
The COVID-19 crisis has spotlighted the public health 
dangers of overcrowding in prison and detention 
facilities, which are even in normal times high risk 
environments for the spread of infectious diseases. 
When COVID-19 was identified as a global pandemic 
in March 2020, the Office of the High Commissioner 
for Human Rights, the UN Special Rapporteur 
on the Right to Health and several international 
organisations called on states to enact emergency 
measures to address and contain the spread of 
COVID-19 in prisons and other closed settings.[38,39] 
Data is lacking, but there is evidence that prisoners 
have been underserved by prevention, testing and 
vaccination efforts.[40]
A global network of 300 organisations highlighted 
the contradiction between overcrowding in prison 
and detention facilities and the physical distancing 
prevention measures forced by COVID-19. Prisons, 
as well as compulsory treatment centres and private 
drug treatment centres, were putting the health and 
lives of those detained in danger.[41] Governments 
were called to limit arrests, promote alternatives to 
punishment and incarceration, and urgently release 
prisoners with underlying health conditions, older 
persons, and those charged or convicted for minor 
or non-violent offences, including drug offences, as 
well as to release people from compulsory treatment 
centres.[42]
Despite these calls, Harm Reduction International’s 
monitoring of prison releases between March and 
June 2020 found that “around a fourth of countries 
implementing decongestion schemes explicitly 
excluded people incarcerated for drug offences; 
effectively prioritising punitive approaches to drug 
control over the health of the prison population and 
the individual”. The 6% global reduction of prison 
population allowed by decongestion schemes fell well 
short of expectations and the political commitments 
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Harm reduction in prisons is effective,  
safe and evidence-based
The World Health Organization, UNAIDS, UN Office on 
Drugs and Crime, International Labour Organization 
and UN Development Programme all recommend the 
implementation of harm reduction in prisons and other 
closed settings as essential public health measures.[44] The 
Outcome Document of the 2016 UN General Assembly 
Special Session on the World Drug Problem urged states 
to provide harm reduction services, including NSPs, 
OAT, naloxone and treatment for HIV and viral hepatitis.[45]
There is a reason these institutions are firmly in favour 
of harm reduction programmes in prisons: the evidence 
shows us that they work.
OPIOID AGONIST THERAPY (OAT)
Systematic reviews show that access to OAT in prison 
reduces illicit opioid use and risk behaviours like 
injection and needle sharing, which, in turn, leads to a 
reduced risk of HIV, viral hepatitis and tuberculosis 
transmission.[46,47] Notably, it is less effective when doses 
are lower, showing the importance of adequate dosage 
when prescribing OAT. Systematic reviews also show that 
OAT is important in the transition between prisons and the 
wider community. Disruption of OAT when entering prison 
is associated with an increase in hepatitis C incidence, 
while pre-release OAT is associated with retention 
in OAT after release.[46] There is also some evidence in 
systematic reviews that enrolment in prison OAT makes 
clients less likely to re-enter prison - a finding supported 
by observational studies in Canada, France and the United 
States.[46,48–50]
A 12-year cohort study in Australia found that there was 
a 74% reduction in all-cause mortality among people 
enrolled in prison OAT, and an 87% reduction in suicide, 
violent or overdose deaths.[51] A similar study in England 
had almost identical findings: a 75% reduction in all-cause 
mortality and an 85% reduction in overdose deaths in the 
first month after release.[52]
NEEDLE AND SYRINGE PROGRAMMES (NSPS)
Several reviews of evidence have shown that prison NSPs 
reduce transmission of viral hepatitis and HIV, to the 
extent that they find no evidence of any transmission 
through injecting drug use in prisons where an NSP is 
operational.[15,53,54] Reviews and observational studies have 
demonstrated the link with NSPs and a reduction in risk 
behaviours. For example, the proportion of people who 
had ever injected drugs reporting syringe sharing in prison 
fell from 20% to 8% after the introduction of a prison NSP 
in Kyrgyzstan.[53,55] All this is achieved with no evidence 
of syringe-related violence where prison NSPs are in 
operation.[15,53,54] The most extensive study of a prison 
NSP was a ten-year study in Ourense, Spain. It found that 
more than 15,000 syringes had been distributed, alongside 
reductions in HIV and hepatitis C prevalence, no increase 
in injecting drug use, no syringe-related violence, and that 
prison staff who had initially been sceptical were satisfied 
that the project was beneficial.[56]
NALOXONE
Systematic reviews demonstrate that take-home naloxone 
programmes reduce mortality from opioid overdose, 
making a strong case for the distribution of naloxone 
to high risk groups like people released from prison.[57] 
Evaluations of such naloxone-on-release programmes 
bear this out. In Scotland, an evaluation found a 50% 
reduction in overdose deaths after the introduction of 
the programme,[58] while in San Francisco, United States, 
32% of people who received naloxone reported using it 
to reverse an overdose.[59] These programmes are also 
effective at engaging and educating new clients on 
overdose risks and response: in San Francisco, 97% of 
participants had never been trained in naloxone before,[59] 
and in Norway the programme improved knowledge of 
risk factors, symptoms and care for opioid overdose.
[60] This is accompanied by evidence from two studies in 
Australia that both people held in prison and prison staff 
are accepting of and willing to participate in take-home 
naloxone programmes.[61,62]
The state of harm reduction in prisons:  
Availability does not mean accessibility1 
1    All data in this section, unless otherwise stated, is from Harm Reduction International’s Global State of Harm Reduction 2020.[5]
OPIOID AGONIST THERAPY (OAT)
In many countries, only a few prisons offer OAT, for example 
Afghanistan, Belgium, Indonesia and Vietnam. In larger 
or federal states, availability of OAT can depend on the 
jurisdiction. For example, in Germany, only one person in 
prison in 2019 reported receiving OAT in the state of Saxony, 
while more than 1,000 received OAT in prisons in Berlin. In 
Canada and the United States, there is a significant difference 
between what is available in federal and state, provincial or 
territorial prisons. 
Even where OAT services are formally available, accessibility 
remains a significant problem. For example, in the whole of 
Ukraine only 93 people in prison are enrolled in OAT. The 
most widespread formal barrier to access is the inability 
to initiate OAT in prison, including in Albania, Cyprus, 
Jordan, Latvia, Lebanon, Montenegro, Morocco and Serbia. 
Unfounded fears of diversion of medication, as well as stigma 
and negative attitudes towards people who use drugs, are 
also reported as barriers to access, including in Canada, 
Germany and Italy.
NEEDLE AND SYRINGE PROGRAMMES (NSPS)
Within the 10 countries where NSPs operate in prisons, they 
are rarely available in all prisons. In Canada, there are NSPs 
only in 11 of 44 federal prisons and none in the provincial or 
territorial prisons that represent 60% of prison capacity in 
the country. In Germany, there is only one syringe-dispensing 
machine in one women’s prison facility in Berlin. 
In prisons where NSPs operate, there are significant barriers 
to their effective implementation as health services, often 
as a result of a ‘zero tolerance’ mentality of prison staff 
towards drug use. In Canada and Spain, these include 
limited confidentiality, long waiting lists, lack of awareness 
of the programme, inappropriate or inadequate injecting 
equipment, and cell inspections that penalise the possession 
of altered or damaged equipment acquired from the NSP.[63]
The world’s first prison drug consumption room (DCR) 
opened in Alberta, Canada in 2019. While the introduction of 
DCRs in prison is commendable, it is not a replacement for 
an effective NSP.
NALOXONE
Harm Reduction International found no reports of naloxone 
being made directly available to people in prison. Availability 
of naloxone to prison staff depends not only on the country, 
but also on sub-national jurisdictions and even individual 
prison authorities. Few countries implement naloxone-on-
release programmes. 
With the exception of Estonia, programmes providing 
naloxone doses and training on release are not systematic 
or present in all prisons. For example, in England, the 
programme only operates in 51% of prisons and only 11% 
of prisoners with a history of opioid use are enrolled. Even in 
Estonia, accessibility remains a concern. Those eligible must 
specifically request to participate but many choose not to 
because of a perceived risk that they will be denied parole 
if they show an intent to use drugs once they are released. 
HIV, VIRAL HEPATITIS AND TUBERCULOSIS 
TREATMENT
Viral hepatitis, HIV and tuberculosis testing and treatment 
are generally available in prison if they are widely available 
in the community. Access to hepatitis C care is more limited, 
and in some contexts can depend on the prison in question. 
For example, in Hungary, Mexico and Ukraine, less than half 
of prisons offer hepatitis C treatment, despite treatment 
being available outside prisons. 
Where treatment is available, there are commonly barriers 
to access. In Canada, prison health services are commonly 
provided by the federal, provincial or territorial correctional 
authority, rather than the relevant department of health. 
This risks damaging the equivalence of care between prisons 
and the broader community. Other barriers include financial 
barriers related to insurance and reimbursement of costs 
in Belgium and Switzerland, as well as long bureaucratic 
processes related to the continuation of treatment on 
entering prison in Italy. 
The Harms of Incarceration 8www.hri.global
84 countries provide OAT 
59 provide OAT in prisons
86 countries provide NSP 
Only 10 provide NSP in prisons
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Redressing the balance: Human rights, punitive 
approaches and neglect
The criminalisation of drug use and possession and 
disproportionate criminal penalties for all drug offences 
result in the over-representation of people who use drugs 
in detention settings. The global ‘war on drugs’ has failed to 
prevent the production, trafficking, and use of drugs. On 
the contrary, there is now plenty of evidence to show that 
the pursuit of a drug-free world has created far more harm 
than the drugs themselves.[64]
People deprived of their liberty retain their human rights, 
including their right to the highest attainable standard of 
health. Fulfilling the right to health includes ensuring access 
to preventive health services and harm reduction services, 
such as OAT and NSPs, for all who require it, including in 
prison settings.[65]
Human rights violations occurring as a consequence of 
drug control, enforcement and deprivation of liberty have 
been a growing concern and progressively more attention 
is being paid on the balancing of concomitant obligations 
within the drug control and human rights international legal 
frameworks.[66] This was bolstered by the publication 
of the International Guidelines on Human Rights and 
Drug Policy in 2019.[67] Constant attention, multi-level 
advocacy and independent monitoring are key elements 
for both human rights and drug policy reform advocates, 
in order to ensure that the destiny of the many facing 
imprisonment is not overlooked.
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